China NMPA Approves NUZYRA® As A Category 1 Innovative Drug For The Treatment Of Patients With Community-Acquired Bacterial Pneumonia (CABP) And Acute Bacterial Skin And Skin Structure Infections (ABSSSI)

By GlobeNewswire NUZYRA demonstrated efficacy against common pathogens in three Phase 3 studies, including pathogens resistant to other antibiotic classes as a potential best-in-class tetracycline NUZYRA is Zai Lab’s fourth new product approval and the first outside oncology SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved its New Drug Application…

Read More